secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001453687-24-000039
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics announces termination of license agreement with Astellas for Xork in Pompe disease
--------------------------------------------------------------------------------

- Astellas terminated the License and Development Agreement effective June 6, 2024, for Xork product candidate.
- Agreement provided exclusive license for Xork in combination with Astellas' gene therapy for Pompe disease.
- Cartesian had received $10M upfront and was eligible for up to $340M in milestones and royalties; no early termination penalties.
- After termination, Cartesian has no further financial commitments or liabilities related to Xork.
- Future milestone and royalty payments from the deal are forfeited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000039/0001453687-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000039/rnac-20240308.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer